By performing structure-based virtual screening, we discovered a clinical antimalarial drug artesunate that enabled to disrupt the association of DDX39B-TRIM28 complex, leading to the decreased expression of DDX39B, and that neutralized the pro-EMT reprogramming and pro-metastatic effects of DDX39B in NSCLC. Here, DDX39B is linked to non-small cell lung carcinoma.